Skip to main content
OpenTrials
Completed

NCT Number: NCT03829683

Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis

The purpose of this research study is to test the safety, tolerability, and effectiveness of Vitamin C (ascorbic acid) intravenous infusion when used to treat alcoholic hepatitis (inflammation of the liver from heavy alcohol use) and sepsis (life-threatening complication of an infection).

Completed

Looking for future studies?

Notify Me

Key information

About this study

Alcoholic hepatitis is inflammation of the liver due to alcohol consumption. It can cause one or more of the following symptoms such as jaundice (yellow discoloration of the eyes and skin), pain on the right side of the abdomen, and is accompanied by an enlarged liver. Sepsis is a life-threatening complication of an infection. As the body tries to fight an infection it sends chemicals into the bloodstream. These chemicals that are trying to fight the infection can cause inflammation. This inflammation can cause damage to many body systems and make them fail. Patients with alcoholic hepatitis and sepsis have low levels of Vitamin C in the bloodstream. Vitamin C has been shown to reduce inflammation and organ dysfunction in patients with severe infections.

The investigators do not yet know if Vitamin C will be effective in alcoholic hepatitis. Taking Vitamin C by mouth is not effective as a treatment in people with this condition so participants will receive the Vitamin C intravenously (IV). Participants will be randomly assigned to receive either Vitamin C or a placebo given through an IV every six hours for four days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Alcoholic Hepatitis diagnosed by one of the following methods:
  • liver biopsy
  • clinical diagnosis based on history of alcohol use, presence of jaundice (yellowing of skin), blood tests indicating liver injury, and absence of other causes of liver injury (autoimmune disease, viral hepatitis, drug toxicity)
  • Suspected or proven infection
  • Presence of systemic inflammatory response to infection (fever, hypothermia (low temperature), tachycardia (fast heart rate), leukocytosis (high white blood cell count), leukopenia (low white blood cell count), high respiratory (breathing) rate, or need for mechanical ventilation (a machine to assist in breathing).
  • Presence of organ failure due to the body's response to infection indicated by any of the following:
  • Hypotension (low blood pressure) or need for medications to raise blood pressure
  • Arterial hypoxemia (low blood oxygen) or need for high flow of oxygen
  • High lactate level (blood test indicating active response to infection)
  • Low urine output despite administration of intravenous fluids
  • Low platelet count (blood test)
  • Coagulopathy (decreased blood clotting ability based on a blood test)
  • High bilirubin (blood test)
  • Mental status changes (confusion or delirium)
  • Absence of drugs present on urine or blood tests that indicate the possibility of liver damage or mental status changes from other causes

Exclusion criteria

  • Allergy to Vitamin C
  • Unable to provide consent
  • Age less than 18 years
  • No intravenous access (IV line) in a patient needing glucose (blood sugar) checks more than twice daily
  • Presence of diabetic ketoacidosis (a serious complication of diabetes)
  • Inability of patient, legally authorized representative and/or physician to commit to full medical support
  • Pregnancy or breast feeding
  • Life expectancy less than 24 hours
  • Active or history of kidney stone
  • History of chronic kidney disease
  • History of glucose-6-phosphate deficiency (a low blood protein that can cause red blood cells to break down)
  • Active cancer (except non-melanoma skin cancer)
  • Uncontrolled gastrointestinal bleeding
  • Other causes of liver injury such as viruses, autoimmune disease, drug toxicity
  • History of severe liver cirrhosis complications including variceal bleeding within the last 3 months, large ascites (fluid accumulation in the abdomen) or hepatocellular carcinoma (liver cancer)
  • History of organ transplantation
  • Initial AST or ALT (blood test indicating a liver problem)
  • Presence of acetaminophen or other drugs on urine or blood toxicology test
  • Non-English speaking
  • Prisoner or other ward of the state

Treatment and study plan

Vitamin C

Drug

200mg/kg/24hours

Other names: ascorbic acid, AscA, Ascor

Dextrose 5% in water

Drug

50mL intravenously every 6 hours

Other names: D5W

Primary outcomes

  1. Change in Model for End Stage Liver Disease (MELD) Score

    Time frame: Baseline and 96 hours

    Change in MELD score from Day 0 to Day 4. MELD score ranges from 6 (least sick) to 40 (most sick) based on blood tests which ranks the degree of sickness from liver disease. The lab tests used to determine the MELD score are creatinine, bilirubin, and international normalized ratio (INR).

Secondary outcomes

  1. Change in Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA) Score

    Time frame: Baseline and 96 hours

    A number that ranges from 0 (least sick) to 24 (most sick) and ranks the degree of sickness from liver failure and several other organ systems in a critically ill person. The score is determined by evaluating a person's liver function, kidney function, nervous system (brain), coagulation (blood clotting), circulation (blood pressure), and respiratory status (breathing)

  2. Change in Aspartate Aminotransferase (AST) Level

    Time frame: Baseline and 96 hours

    Standard blood test used to determine the severity and nature of liver problems.

  3. Change in Alanine Aminotransferase (ALT) Level

    Time frame: Baseline and 96 hours

    Standard blood test used to determine the severity and nature of liver problems.

  4. Change in Total Bilirubin

    Time frame: Baseline and 96 hours

    Standard blood test used to determine the severity and nature of liver problems.

  5. Change in Alkaline Phosphatase

    Time frame: Baseline and 96 hours

    Standard blood test used to determine the severity and nature of liver problems.

  6. Change in Albumin

    Time frame: Baseline and 96 hours

    Standard blood test used to determine the severity and nature of liver problems.

  7. Number of Treatment-related Adverse Events as Assessed by CTCAE v5.0

    Time frame: up to 96 hours

    Observation about the need to change the dose of study medication and symptoms such as headache, dizziness, dry mouth, nausea, vomiting, flushing, rash, or hypotension (low blood pressure)

  8. Changes to Corrected QT Interval (QTc)

    Time frame: Baseline and 96 hours

    An electrocardiogram (ECG or test of the electrical activity of the heart) is performed to determine if there are changes to the heart rhythm.

  9. Changes to Urine pH

    Time frame: Baseline and 96 hours

    Urine samples are collected to determine changes in pH (acidity) that could indicate a risk for kidney stones. The pH scale ranges from 0 to 14, with smaller numbers meaning more acidic and higher numbers meaning more basic. A pH of 7 is considered to be neutral. Normal levels of urine pH range from 4.6 - 8 on the pH scale.

  10. Changes to Urine Microscopy

    Time frame: Baseline and 96 hours

    Urine samples are collected to check for the presence of crystalluria (microscopic crystals) that could indicate a risk for kidney stones.

  11. Changes to Level of Medical Care

    Time frame: up to 168 hours

    Documentation of the need for more intensive medical care such as ventilator (breathing machine) or vasopressors (intravenous medications use increase blood pressure) when not needed at baseline

  12. ICU-free Days

    Time frame: Day 28

    The number of days not spent in an intensive care unit (ICU)

  13. Number of Deaths Due to Any Cause

    Time frame: Day 28

    Any cause of death that is anticipated or unanticipated

  14. Number of Deaths Due to Any Cause

    Time frame: Day 90

    Any cause of death that is anticipated or unanticipated

  15. Hospital-free Days

    Time frame: Day 90

    The number of days spent outside of the hospital

Sponsors and collaborators

Lead sponsor

Virginia Commonwealth University

Other

Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Registry information

Acronym: CITRIS-AH

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Feb 4, 2019
Registry last updated
Aug 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.